Wockhardt Pharma
Wockhardt exits its US generics business
As part of the strategic realignment of its US business, the company has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.
1 min read11 Jul 2025How Wockhardt is packing for the road less travelled
Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for weight loss and anti-diabetic medicine, as it pivots away from the US generics market.
7 min read3 Apr 2025Wockhardt shares jump 4% despite the stock market crash after an update on antibiotic Zaynich. Check details
Wockhardt's share price rose 4 per cent in intraday trade on the BSE on January 13, despite weak market sentiment, after announcing over 97 per cent efficacy of its antibiotic Zaynich against resistant infections. The stock has surged nearly 210 per cent in the past year.
2 min read13 Jan 2025Wockhardt exits its US generics business
As part of the strategic realignment of its US business, the company has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.
1 min read11 Jul 2025Wockhardt shares jump 4% despite the stock market crash after an update on antibiotic Zaynich. Check details
Wockhardt's share price rose 4 per cent in intraday trade on the BSE on January 13, despite weak market sentiment, after announcing over 97 per cent efficacy of its antibiotic Zaynich against resistant infections. The stock has surged nearly 210 per cent in the past year.
2 min read13 Jan 2025